tirzepatide cvot vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM 🫀 EASD 2025: Tirzepatide (SURPASS-CVOT)

Zealand Pharma's Petrelintide more tolerable

Trial participation is not the same as receiving a routine prescription

KARINE CASTRO (verified owner) Rated 5 out of 5 Elizabeth Sigrest (verified owner) Rated 5 out of 5 Got mine Cicero Gondim (verified owner) Rated 5 out of 5 Anonymous (verified owner) Rated 5 out of 5 Effective Related products UPB AOD-9604 5MG 5.00 out of 5 UPB CagriSema 5MG/5MG 5.00 out of 5 UPB CJC/IPA 5MG/5MG without DAC 5.00 out of 5 UPB GHK-Cu 50MG UPB Melanotan II -10mg UPB MOTS-C 10MG 5.00 out of 5

New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, hemodynamics profiles, quality of life, and subsets of hypertension

Higher doses of tirzepatide were tolerable where equivalent doses of a pure GLP-1 agonist would not be

Both medications work by slowing digestion, increasing satiety, and regulating insulin response helping you eat less and lose more